Neuropathic pain is a worldwide epidemic that occurs in 3 to 8% of individuals in industrialized countries and is often refractory to existing treatments. Drugs currently available to target
neuropathic pain are, at best, moderately effective and include
antidepressants,
gabapentin,
NMDA receptor antagonists, as well as other
anticonvulsants, all of which are limited by their adverse-effect profiles.
Cannabinoid drugs are emerging as a promising class of drugs to treat
neuropathic pain and have been tested for
analgesic effects in a range of
chronic pain conditions. Data show that
cannabinoids are often effective in individuals with
refractory pain receiving concomitant
analgesic drugs. Clinical studies on
cannabinoids for the treatment of
neuropathic pain are reviewed, focusing on clinical trials published within the last five years. Data from large, well-controlled studies show that
cannabinoids are moderately effective in reducing
chronic pain and that side effects are comparable to existing treatments, suggesting that
cannabinoids can play a useful role in the management of chronic
pain. Like other drugs for
neuropathic pain,
cannabinoids have a dose titration that is limited by psychoactive side effects. The development of
cannabinoid drugs to target
neuropathic pain with improved therapeutic ratios will depend upon the development of
cannabinoid treatments with reduced psychoactivity.